专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060142346A1 S-lansoprazole compositions and methods 审中-公开
标题翻译： S-兰索拉唑组合物和方法
公开(公告)号：US20060142346A1
公开(公告)日：2006-06-29
申请号：US11359698
申请日：2006-02-22
申请人： Timothy Barberich , William Yelle , Paul Rubin
发明人： Timothy Barberich , William Yelle , Paul Rubin
IPC分类号： A61K31/4439
CPC分类号： A61K31/4439
摘要： Methods and compositions are disclosed utilizing optically pure (−) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Lansoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
摘要翻译：公开了使用光学纯的（ - ）兰索拉唑治疗人类溃疡的方法和组合物，同时显着减少与兰索拉唑的外消旋混合物相关的副作用的伴随的责任。光学纯的（ - ）异构体也可用于治疗胃食管反流。（ - ）兰索拉唑是释放H +的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，例如Zollinger-Ellison综合征。

2. 发明申请

US20060019970A1 Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites 审中-公开
标题翻译：使用齐拉西酮代谢物治疗精神抑制和相关疾病的方法和组合物
公开(公告)号：US20060019970A1
公开(公告)日：2006-01-26
申请号：US11177476
申请日：2005-07-11
申请人： Timothy Barberich , Paul Rubin , William Yelle
发明人： Timothy Barberich , Paul Rubin , William Yelle
IPC分类号： A61K31/519
CPC分类号： A61K45/06 , A61K31/496 , C07D417/12
摘要： The invention relates to novel methods using, and pharmaceutical compositions comprising, ziprasidone metabolites. The methods and compositions of the invention are suitable for the treatment of neuroleptic and related disorders. The invention further encompasses methods of preparing ziprasidone sulfoxide and ziprasidone sulfone.
摘要翻译：本发明涉及使用包含齐拉西酮代谢物的药物组合物的新方法。本发明的方法和组合物适用于治疗精神安定药和相关疾病。本发明还包括制备齐拉西酮亚砜和齐拉西酮砜的方法。

3. 发明申请

US20050154018A1 Method for treating and preventing disorders using optically pure (+) norcisapride 审中-公开
标题翻译：使用光学纯（+）诺西沙必利治疗和预防疾病的方法
公开(公告)号：US20050154018A1
公开(公告)日：2005-07-14
申请号：US10998566
申请日：2004-11-30
申请人： Paul Rubin , Timothy Barberich
发明人： Paul Rubin , Timothy Barberich
IPC分类号： A61K31/445 , A61K31/4468 , A61P1/00 , A61P9/06 , A61P11/06 , A61P25/00 , A61P43/00
CPC分类号： A61K31/445 , A61K31/4468
摘要： Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) stereoisomer.
摘要翻译：使用（+）诺西沙必利或其药学上可接受的盐的预防，治疗或治疗呼吸暂停，呼吸暂停障碍，贪食症，肠易激综合征，尿失禁，心动过缓，缓慢性心律失常，晕厥，其他障碍或其症状的方法，基本上不含（ - ）立体异构体。

4. 发明申请

US20050228052A1 Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine 审中-公开
标题翻译：使用（S） - 二甲基西布曲明治疗，预防和控制睡眠障碍的方法
公开(公告)号：US20050228052A1
公开(公告)日：2005-10-13
申请号：US11044566
申请日：2005-01-28
申请人： Timothy Barberich
发明人： Timothy Barberich
IPC分类号： A61K31/137
CPC分类号： A61K31/137
摘要： This invention relates, in part, to methods of treating, preventing and/or managing a sleep disorder using enantiomerically pure (S)-didesmethylsibutramine, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate or prodrug thereof. Specific methods for treating, preventing and/or managing insomnia, wakefulness, circadian rhythm sleep disorders, shift work sleep disorder, and periodic limb movement disorder are also disclosed.
摘要翻译：本发明部分地涉及使用对映异构纯的（S） - 二甲基西布曲明或其药学上可接受的盐，水合物，溶剂合物，包合物或前药治疗，预防和/或治疗睡眠障碍的方法。还公开了治疗，预防和/或治疗失眠，觉醒，昼夜节律睡眠障碍，转移工作睡眠障碍和周期性肢体运动障碍的具体方法。

5. 发明申请

US20070299055A1 COMBINATION OF SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION 有权
标题翻译：消融和神经递质调节剂的组合以及改善睡眠质量和治疗呕吐的方法
公开(公告)号：US20070299055A1
公开(公告)日：2007-12-27
申请号：US11761235
申请日：2007-06-11
申请人： Karim Lalji , Timothy Barberich , Judy Caron , Thomas Wessel
发明人： Karim Lalji , Timothy Barberich , Judy Caron , Thomas Wessel
IPC分类号： A61K31/495 , A61K31/13 , A61K31/135 , A61K31/165 , A61K31/535 , A61P43/00 , A61K31/55 , A61K31/34 , A61K31/38 , A61K31/445
CPC分类号： A61K31/4985 , A61K31/137 , A61K31/138 , A61K31/495 , A61K31/724 , A61K45/06 , A61K2300/00
摘要： One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT2A modulator or DRI.
摘要翻译：本发明的一个方面涉及含有两种或更多种活性剂的药物组合物，当它们一起被用于治疗，例如失眠和/或抑郁症时。药物组合物的第一组分是调节GABA受体的化合物。药物组合物的第二组分是5-羟色胺再摄取抑制剂，去甲肾上腺素再摄取抑制剂，5-HT 2AA调节剂或多巴胺再摄取抑制剂。在某些实施方案中，药物组合物包含依佐匹克。在优选的实施方案中，药物组合物包含依佐匹克和氟西汀。本发明还涉及一种治疗睡眠异常，治疗失眠，治疗抑郁症，增强抗抑郁药治疗，引发剂量保留作用，减少抑郁症复发，改善抗抑郁治疗疗效或提高抗抑郁治疗耐受性的方法，包括向有需要的患者共同施用GABA受体调节化合物; 和SRI，NRI，5-HT 2A调节剂或DRI。

6. 发明申请

US20050164987A1 Melatonin combination therapy for improving sleep quality 审中-公开
标题翻译：褪黑激素联合疗法改善睡眠质量
公开(公告)号：US20050164987A1
公开(公告)日：2005-07-28
申请号：US11020654
申请日：2004-12-22
申请人： Timothy Barberich
发明人： Timothy Barberich
IPC分类号： A61K31/195 , A61K31/4045 , A61K31/405 , A61K31/4164 , A61K31/4985 , A61K31/5513 , A61K31/724 , A61K45/06
CPC分类号： A61K45/06 , A61K31/4045 , A61K31/4985 , A61K2300/00
摘要： One aspect of the present invention relates to pharmaceutical compositions comprising a sedative agent; and melatonin or a melatonin analog, collectively referred to as “melatonin agents.” In a preferred embodiment, the sedative agent is eszopiclone. The pharmaceutical compositions of the invention are useful in the treatment of various sleep disorders. In addition, the present invention also relates to a method of treating a patient suffering from a sleep abnormality or insomnia comprising administering a therapeutically effective amount of a pharmaceutical composition of the invention.
摘要翻译：本发明的一个方面涉及包含镇静剂的药物组合物; 和褪黑激素或褪黑素类似物，统称为“褪黑激素剂”。在优选的实施方案中，镇静剂是依佐匹克隆。本发明的药物组合物可用于治疗各种睡眠障碍。此外，本发明还涉及治疗患有睡眠异常或失眠的患者的方法，包括施用治疗有效量的本发明的药物组合物。

7. 发明申请

US20050267176A1 Dopamine-agonist combination therapy for improving sleep quality 审中-公开
标题翻译：多巴胺 - 激动剂联合治疗以改善睡眠质量
公开(公告)号：US20050267176A1
公开(公告)日：2005-12-01
申请号：US11052719
申请日：2005-02-07
申请人： Timothy Barberich
发明人： Timothy Barberich
IPC分类号： A61K31/137 , A61K31/425 , A61K31/4985 , A61K45/06
CPC分类号： A61K45/06 , A61K31/137 , A61K31/425 , A61K31/4985 , A61K2300/00
摘要： The present invention generally relates to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzopiclone. The pharmaceutical compositions of the invention are useful in the treatment of restless-leg syndrome and periodic-limb-movement disorder, as well as various sleep disorders. In addition, the present invention relates to a method of treating a patient suffering from restless-leg syndrome, periodic-limb-movement disorder, a sleep abnormality, or insomnia, comprising coadministering a therapeutically effective amount of a dopamine agonist and a therapeutically effective amount of a sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzopiclone.
摘要翻译：本发明一般涉及包含多巴胺激动剂和镇静剂的药物组合物。在优选的实施方案中，多巴胺激动剂是光学纯的（S） - 二甲基甲基西布曲明。在优选的实施方案中，镇静剂是光学纯的（S） - 佐匹克隆或光学纯的（S）-N-去甲基佐匹克隆。在优选的实施方案中，多巴胺激动剂是光学纯的（S） - 二甲基甲基西布曲明; 并且镇静剂是光学纯的（S） - 佐匹克隆或光学纯的（S）-N-去甲基佐匹克隆。本发明的药物组合物可用于治疗不宁腿综合征和周期性肢体运动障碍以及各种睡眠障碍。此外，本发明涉及治疗患有不宁腿综合征，周期性肢体运动障碍，睡眠异常或失眠的患者的方法，包括共同施用治疗有效量的多巴胺激动剂和治疗有效量的镇静剂。在优选的实施方案中，多巴胺激动剂是光学纯的（S） - 二甲基甲基西布曲明。在优选的实施方案中，镇静剂是光学纯的（S） - 佐匹克隆或光学纯的（S）-N-去甲基佐匹克隆。在优选的实施方案中，多巴胺激动剂是光学纯的（S） - 二甲基甲基西布曲明; 并且镇静剂是光学纯的（S） - 佐匹克隆或光学纯的（S）-N-去甲基佐匹克隆。

8. 发明申请

US20050215521A1 Modafinil combination therapy for improving sleep quality 审中-公开
标题翻译：莫达非尼组合疗法改善睡眠质量
公开(公告)号：US20050215521A1
公开(公告)日：2005-09-29
申请号：US11018869
申请日：2004-12-21
申请人： Karim Lalji , Timothy Barberich
发明人： Karim Lalji , Timothy Barberich
IPC分类号： A61K31/165 , A61K31/195 , A61K31/4164 , A61K31/495 , A61K31/7008 , A61K31/724 , A61K45/06
CPC分类号： A61K45/06 , A61K31/165 , A61K31/195 , A61K31/4164 , A61K31/495 , A61K31/7008 , A61K31/724 , A61K2300/00
摘要： One aspect of the present invention relates to pharmaceutical compositions comprising a compound that modulates the orexin system and a sedative agent. In a preferred embodiment, the compound that modulates the orexin system is modafinil and the sedative agent is eszopiclone. The pharmaceutical compositions of the invention are useful in the treatment of various sleep disorders. In addition, the present invention relates to a method of treating a patient suffering from a sleep abnormality or insomnia comprising administering a therapeutically effective amount of a pharmaceutical composition of the invention.
摘要翻译：本发明的一个方面涉及包含调节食欲素系统的化合物和镇静剂的药物组合物。在优选的实施方案中，调节食欲素系统的化合物是莫达非尼，镇静剂是依佐匹克隆。本发明的药物组合物可用于治疗各种睡眠障碍。此外，本发明涉及治疗患有睡眠异常或失眠的患者的方法，包括给予治疗有效量的本发明的药物组合物。

9. 发明申请

US20050192344A1 Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites 有权
标题翻译：使用西酞普兰，依他普仑或西酞普兰代谢物治疗或预防偏头痛或头痛
公开(公告)号：US20050192344A1
公开(公告)日：2005-09-01
申请号：US11060067
申请日：2005-02-17
申请人： Timothy Barberich
发明人： Timothy Barberich
IPC分类号： A61K31/343
CPC分类号： A61K31/343
摘要： Methods for prophylaxis of or treating or preventing migraine or migraine headaches, or other headache disorders include administering to a subject in need of treatment a therapeutically effective amount of citalopram, escitalopram, or a racemic or optically pure citalopram metabolite, or pharmaceutically acceptable salts, solvates, polymorphs, or hydrates thereof.
摘要翻译：用于预防或治疗或预防偏头痛或偏头痛或其他头痛障碍的方法包括向需要治疗的受试者施用治疗有效量的西酞普兰，依他普仑或外消旋或光学纯的西酞普兰代谢物或其药学上可接受的盐溶剂化物，多晶型物或其水合物。

10. 发明申请

US20050176680A1 Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression 审中-公开
标题翻译：镇静剂和神经递质调节剂的组合，以及改善睡眠质量和治疗抑郁症的方法
公开(公告)号：US20050176680A1
公开(公告)日：2005-08-11
申请号：US11007795
申请日：2004-12-08
申请人： Karim Lalji , Timothy Barberich , Judy Caron , Thomas Wessel
发明人： Karim Lalji , Timothy Barberich , Judy Caron , Thomas Wessel
IPC分类号： A61K31/137 , A61K31/138 , A61K31/495 , A61K31/4985 , A61K31/724 , A61K45/06
CPC分类号： A61K31/4985 , A61K31/137 , A61K31/138 , A61K31/495 , A61K31/724 , A61K45/06 , A61K2300/00
摘要： One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT2A modulator or DRI.
摘要翻译：本发明的一个方面涉及含有两种或更多种活性剂的药物组合物，当它们一起被用于治疗，例如失眠和/或抑郁症时。药物组合物的第一组分是调节GABA受体的化合物。药物组合物的第二组分是5-羟色胺再摄取抑制剂，去甲肾上腺素再摄取抑制剂，5-HT 2AA调节剂或多巴胺再摄取抑制剂。在某些实施方案中，药物组合物包含依佐匹克。在优选的实施方案中，药物组合物包含依佐匹克和氟西汀。本发明还涉及一种治疗睡眠异常，治疗失眠，治疗抑郁症，增强抗抑郁药治疗，引发剂量保留作用，减少抑郁症复发，改善抗抑郁治疗疗效或提高抗抑郁治疗耐受性的方法，包括向有需要的患者共同施用GABA受体调节化合物; 和SRI，NRI，5-HT 2A调节剂或DRI。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式